SPOTLIGHT: Back end deal for CrystalGenomics

CrystalGenomics/CG Pharmaceuticals announced a strategic alliance agreement with ProQuest Investments to identify and develop orally available drugs that modulate the HIF Prolyl Hydroxylase enzyme system. Under the agreement, CrystalGenomics will receive up to $6 million in upfront and initial research funding from Palkion, in addition to development and sales milestone payments of potentially more than $200 million. Release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.